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Abstract
Background: Coronary artery disease accelerates heart failure progression, leading to poor prognosis and a
substantial increase in morbidity and mortality. This study was aimed to assess the impact of coronary artery
disease on all-cause mortality, myocardial infarction (MI), and ischemic stroke (IS) among hospitalized newly-
diagnosed heart failure (HF) patients with left ventricular systolic dysfunction (LVSD).
Methods: This retrospective cohort study included Medicare patients (aged ≥65 years) with ≥1 inpatient heart
failure claim (index date = discharge date) during 01JAN2007-31DEC2013. Patients were required to have
continuous enrollment for ≥1-year pre-index date (baseline: 1-year pre-index period) without a prior heart failure
claim (in the 1 year pre-index prior to the index hospital admission); follow-up ran from the index date to death,
disenrollment from the health plan, or the end of the study period, whichever occurred first. HF with LVSD patients,
identified with diagnosis codes of systolic dysfunction (excluding baseline atrial fibrillation), were stratified based on
prevalent coronary artery disease at baseline into coronary artery disease and non-coronary artery disease cohorts.
Main outcomes were occurrence of major adverse cardiovascular events including all-cause mortality, myocardial
infarction, and ischemic stroke. Propensity score matching (PSM) was used to balance patient characteristics.
Kaplan-Meier curves of ACM and cumulative incidence distribution of MI/IS were presented.
Results: Of 22,230 HF with LVSD patients, 15,827 (71.2%) had coronary artery disease and were overall more likely
to be younger (79.8 vs 80.9 years), male (49.6% vs. 35.6%), white (86.2% vs 81.4%), with more prevalent
comorbidities including hypertension (80.7% vs 74.3%), hyperlipidemia (67.7% vs 46.7%), and diabetes (46.3% vs 35.
8%) (all p < 0.0001). After propensity score matching, cohorts included 5792 patients each. The coronary artery
disease cohort had significantly higher cumulative incidence of myocardial infarction and ischemic stroke at the
end of 7-year follow-up vs non-coronary artery disease (myocardial infarction = 50.0% vs 18.0%; ischemic stroke = 23.
3% vs 18.7%; all p < 0.0001). Follow-up all-cause mortality rates were similar between the two cohorts.
Conclusions: HF with LVSD patients with coronary artery disease had significantly higher incidence of ischemic
stroke and myocardial infarction, but similar all-cause mortality compared to those without coronary artery disease.
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Highlights
 Our study assessed hospitalized heart failure with
systolic dysfunction patients
 Among these patients, 71% had coronary artery
disease
 Incidence of myocardial infarction was higher in
those with coronary artery disease
 Coronary artery disease is also associated with
higher incidence of ischemic stroke
 Mortality was similar between patients with and
without coronary artery disease
Background
Coronary artery disease (CAD) is the most common
cause of heart failure (HF) and remains the primary
cause of death, particularly in developed countries [1].
Approximately two-thirds of HF cases are attributable to
underlying CAD [1]. HF is a chronic progressive disease
that affected ~ 6 million people in the United States in
2012 [2]. Due to the aging of the US population and in-
creased life expectancy, prevalence of HF is expected to
increase to approximately 46% by 2030, resulting in > 8
million adults with HF [3]. HF due to left ventricular
systolic dysfunction (LVSD), accounts for nearly half of
HF cases [4]. Common risk factors for HF, such as
hypertension and diabetes, also promote the develop-
ment of atherosclerosis leading to CAD [5]. CAD accel-
erates the progression of HF with LVSD, leading to poor
prognosis and a substantial increase in morbidity and
mortality [6]. Given the increased burden of CAD in HF
patients and the fact that CAD may have important
therapeutic implications, the Heart Failure Society of
America recommends testing for CAD in HF patients
[1, 7]. Despite continuous improvements in HF manage-
ment, morbidity and mortality remain unacceptably
high: 22% of patients die within 1 year, and ~ 50% pa-
tients die within 5 years [3, 8]. The concomitant pres-
ence of CAD in HF patients has been reported to elevate
the risk for cardiovascular (CV) outcomes including
myocardial infarction (MI), IS, arrhythmia, mortality,
and hospitalizations [9]. However, limited data evaluat-
ing the real world incidence of CV-related outcomes
among hospitalized newly-diagnosed HF with LVSD pa-
tients with CAD and without AF is available. Addition-
ally, HF patients without an atrial fibrillation (AF)
diagnosis remain at considerably high risk for CV out-
comes [10].
Methods
This was a longitudinal, retrospective cohort study using a
5% random sample of the US Medicare database, includ-
ing patients aged ≥65 years from 01JAN2006-31DEC2013.
Medicare provides health insurance coverage to ~ 42
million persons aged ≥65 years as well as nearly 9 million
persons aged < 65 years with end-stage kidney disease
or a disability. For each beneficiary, claims from all set-
tings of care were linked to create a longitudinal record
of their health encounters, diagnoses, and drug pre-
scriptions. No patient identity or medical records were
disclosed for the purposes of this study. Since the data
used for this study were de-identified and only aggre-
gate results were reported, the study was approved by
the Institutional Review Board as exempt. Compliance
with all applicable laws and the Health Insurance Port-
ability and Accountability Act (HIPAA) regulations
were maintained.
Patients were included in the study if they had ≥1 in-
patient claim for HF (International classification of Dis-
eases, 9th Revision, Clinical Modification [ICD-9-CM] code
428.xx) during the identification period (01JAN2007-31-
DEC2013); the discharge date of the first hospitalization
was designated as the index date. Additionally, patients
were required to have continuous enrollment in their
Medicare health plan with medical and pharmacy benefits
for ≥1-year pre-index date (baseline period: 1-year
pre-index period including the index hospital admission).
The follow-up period included the period after the index
date until death, disenrollment from health plan, or end of
the study period, whichever occurred first. Patients with
evidence of HF during the 1-year period prior to the index
hospital admission were excluded (Fig. 1).
HF patients with LVSD (ICD-9 CM codes 428.1,
428.20–428.23, 428.40–428.43) on the index date and
without evidence of AF (ICD-9-CM code 427.31) in
the baseline period (including the index hospital ad-
mission) were further stratified based on evidence of
significant CAD in the baseline (including the index
hospital admission) into CAD and non-CAD cohorts.
We have included hospitalized HF patients without
atrial fibrillation (AF) given the limited evidence on
the burden of clinical outcomes as well as the con-
flicting evidence on the benefit of anticoagulation use
in these patients [4]. Evidence of CAD was defined as
having previously documented CAD (ICD-9-CM
codes 410.x-414.x, 429.2, V45.81), history of prior cor-
onary artery bypass graft (Current Procedural Termin-
ology [CPT] codes 33,510–33,536 or ICD-9 CM
procedure codes 36.10–36.17, 36.19), or history of
percutaneous coronary intervention with or without
stent (CPT codes 92,980–92,996 or ICD-9-CM codes
00.66, 36.01–36.09). Throughout the manuscript, in-
cluded hospitalized HF patients with LVSD and with-
out AF will be referred to as “HF with LVSD
patients.” Additionally, newly-diagnosed HF patients
identified with an inpatient or outpatient claim were in-
cluded in a sensitivity analysis to see if there existed any
differences in this population from the hospitalized HF
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population given the fact that the study included elderly
patients aged ≥65 years.
Baseline measures
Patient demographics including age, sex, race, and US geo-
graphic region as of the index date were assessed. Clinical
characteristics including Charlson comorbidity index (CCI)
score, CHADS2 score (congestive HF, hypertension, age ≥
75 years, diabetes mellitus, prior stroke, or transient ische-
mic attack [TIA]), comorbidities (hypertension, hyperlipid-
emia, arrhythmia, anemia, diabetes, trauma, chronic renal
insufficiency, malignant neoplasm, pneumonia, peripheral
artery disease, anasarca, chronic obstructive pulmonary
disease, dementia, hepatic disease, rheumatoid arthritis, de-
pression, coagulation defect, obesity, varicose veins, throm-
bophilia, inflammatory bowel disease, arterial embolic
events, peptic ulcer, alcohol abuse, pulmonary edema,
bleeding diathesis), and prior clinical events (IS, TIA, ven-
ous thromboembolism [VTE], major bleeding) during the
baseline period were assessed.
Outcome measures
Main outcomes were occurrence of major adverse car-
diovascular events including ACM, MI (ICD-9-CM
codes: 410,412) and IS (ICD-9-CM codes: 433.01,
433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11,
Fig. 1 Patient Selection Criteria. AF: atrial fibrillation; CAD: coronary artery disease; HF: heart failure; LVSD: HF patients with left ventricular systolic
dysfunction. *The final HF sample size used for the sensitivity analysis is less than the sum of the inpatient and outpatient populations because
the populations were not mutually exclusive. **The HF sample used for main analysis
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434.91, 436). ACM rates, and cumulative incidence of
MI and IS with death as a competing risk, were esti-
mated by 60-day intervals during the first year of fol-
low-up and by each year during the entire follow-up period
(maximum 7 years) among newly-diagnosed “HF with
LVSD patients” in the CAD versus non-CAD cohorts.
Statistical analysis
Descriptive statistics (means and standard deviations for
continuous variables, numbers and percentages for di-
chotomous/polychotomous variables) were provided for
all study variables, including baseline demographic and
clinical characteristics in the CAD and non-CAD co-
horts. Statistical tests of significance (chi-square for cat-
egorical variables and t-test for continuous variables)
were conducted to assess differences between the co-
horts. Propensity Score Matching (PSM) was used to
achieve baseline balance for patient characteristics. The
propensity score was calculated via a logistic regression
model, and the covariates adjusted in the model in-
cluded all demographics, CCI score, CHADS2 score, co-
morbidities, and prior baseline clinical events. Each
CAD patient was matched to a non-CAD patient within
0.01 units of the propensity score. The adequacy of the
matching procedure was assessed by standardized differ-
ence for each of the matching variables; a difference of
< 10% is considered well balanced [11]. Between the
CAD and non-CAD cohorts, Kaplan-Meier (KM) curves
of ACM were compared using the log-rank test; cumula-
tive incidence distribution for MI and IS was compared
using Gray’s test [12, 13]. All analyses were conducted
using SAS® statistical software (Version 9.3, SAS Insti-
tute, Cary, North Carolina, 2012).
Results
A total of 312,151 newly-diagnosed HF patients with ei-
ther an inpatient or outpatient claim were identified,
which included 207,535 hospitalized HF patients. These
hospitalized HF patients comprised the study sample for
the main analysis. Among them, 22,230 (10.7%) were di-
agnosed with LVSD on the index date and had no evi-
dence of AF in the baseline period. Among newly-
diagnosed hospitalized HF with LVSD patients, 15,827
(71.2%) were included in the CAD cohort and 6403
(28.8%) were included in the non-CAD cohort (Fig. 1).
Baseline demographics and clinical characteristics
HF with LVSD patients in the CAD cohort were younger
(79.8 vs 80.9 years) and were more frequently male
(49.6% vs 35.6%) and white (86.2% vs 81.4%). Addition-
ally, HF with LVSD patients in the CAD cohort had
higher mean CCI scores (4.4 vs 3.5), CHADS2 scores
(3.3 vs 3.0), and a higher percentage of comorbid hyper-
tension (80.7% vs 74.3%), hyperlipidemia (67.7% vs
46.7%), diabetes (46.3% vs 35.8%), chronic renal insuffi-
ciency (32.1% vs 27.1%), arrhythmia (30.4% vs 23.2%),
and peripheral artery disease (23.1% vs 13.0%). Also, the
CAD cohort had a higher proportion of HF with LVSD
patients diagnosed with IS (17.0% vs 10.9%) and TIA
(3.9% vs 3.0%), but a lower proportion of patients diag-
nosed with VTE (5.8% vs 8.4%) in the baseline period
(Table 1).
Post-propensity score matching results
After 1:1 PSM, each cohort included 5792 patients. The
cohorts were well-balanced based on baseline demo-
graphic and clinical characteristics, with a standardized
difference of < 10% after matching (Table 1). The median
follow-up period was 15.7 months in both cohorts.
ACM, MI, and IS rates among HF patients with and
without CAD in the entire follow-up period after PSM
All-cause mortality rate
The ACM rate in the CAD cohort was 34% at the end of
1 year, followed by 54 and 68% at the end of years 3 and
5, respectively (Fig. 2). The ACM rate did not signifi-
cantly differ between the CAD and non-CAD cohorts
(34.1% vs 35.2%, p = 0.0511) during the first year of
follow-up nor during the entire duration of follow-up
(80.0% vs 79.5%, p = 0.1124).
Cumulative incidence of myocardial infarction with death
as competing risk
The cumulative incidence rate of MI in the CAD cohort
was 36% at the end of 1 year, followed by 45, and 49% at the
end of years 3 and 5, respectively (Fig. 3). The CAD cohort
had a significantly higher cumulative incidence of MI during
the first year of follow-up (36.1% vs 9.2%, p < 0.0001), as well
as a significantly higher cumulative incidence rate of MI
(50.0% vs 18.0%, p < 0.0001) during the entire follow-up
period.
Cumulative incidence of ischemic stroke with death as
competing risk
The cumulative incidence rate of IS in the CAD cohort
was 12% at the end of 1 year, followed by 19 and 22% at
the end of years 3 and 5, respectively (Fig. 4). As was ob-
served with MI, the CAD cohort had a significantly
higher cumulative incidence of IS during the first year
(11.7% vs 9.4%, p < 0.0001) and the entire follow-up
period (23.3% vs 18.7%, p < 0.0001).
Sensitivity analysis
A total of 312,151 newly-diagnosed HF patients including
either inpatient (N = 207,535) or outpatient (N = 133,009)
claims were included for sensitivity analysis, of which
28,983 (9.3%) were diagnosed with LVSD on the index date
and had no evidence of AF in the baseline period. Among
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Table 1 Baseline Demographic and Clinical Characteristics of HF with LVSD Patients with and without CAD
Baseline Characteristics of HF Patients
with LVSD
Before PSM After 1:1 PSM
CAD Cohort
(N = 15,827 )
Non-CAD Cohort
(N = 6,403)
CAD Cohort
(N = 5,792 )
Non-CAD Cohort
(N = 5,792)
N/Mean %/SD N/Mean %/SD p-value Std N/Mean %/SD N/Mean %/SD p-value Std
Age (Mean) 79.8 8.3 80.9 8.7 <.0001 13.0 80.8 8.5 80.7 8.6 0.4521 1.4
Age Group
65-74 4,849 30.6% 1,714 26.8% <.0001 8.6 1,566 27.0% 1,573 27.2% 0.8837 0.3
75-84 6,068 38.3% 2,296 35.9% 0.0005 5.1 2,123 36.7% 2,113 36.5% 0.8470 0.4
85+ 4,910 31.0% 2,393 37.4% <.0001 13.4 2,103 36.3% 2,106 36.4% 0.9538 0.1
Gender
Male 7,852 49.6% 2,278 35.6% <.0001 28.7 2,200 38.0% 2,174 37.5% 0.6183 0.9
Female 7,975 50.4% 4,125 64.4% <.0001 28.7 3,592 62.0% 3,618 62.5% 0.6183 0.9
Race/Ethnicity
White 13,636 86.2% 5,212 81.4% <.0001 12.9 4,802 82.9% 4,787 82.6% 0.7120 0.7
Black 1,436 9.1% 924 14.4% <.0001 16.7 755 13.0% 760 13.1% 0.8904 0.3
Hispanic 145 0.9% 57 0.9% 0.8535 0.3 44 0.8% 50 0.9% 0.5344 1.2
Asian 206 1.3% 65 1.0% 0.0780 2.7 51 0.9% 63 1.1% 0.2587 2.1
Native American 285 1.8% 110 1.7% 0.6723 0.6 112 1.9% 101 1.7% 0.4468 1.4
Other 92 0.6% 23 0.4% 0.0366 3.2 22 0.4% 23 0.4% 0.8813 0.3
Unknown 27 0.2% 12 0.2% 0.7861 0.4 6 0.1% 8 0.1% 0.5928 1.0
US Geographic Region
Northeast 3,219 20.3% 1,271 19.9% 0.4113 1.2 1,170 20.2% 1,165 20.1% 0.9078 0.2
Midwest 4,149 26.2% 1,641 25.6% 0.3673 1.3 1,459 25.2% 1,491 25.7% 0.4950 1.3
South 6,370 40.2% 2,506 39.1% 0.1260 2.3 2,265 39.1% 2,284 39.4% 0.7177 0.7
West 2,051 13.0% 970 15.1% <.0001 6.3 882 15.2% 838 14.5% 0.2503 2.1
Other 38 0.2% 15 0.2% 0.9357 0.1 16 0.3% 14 0.2% 0.7146 0.7
Comorbidity Indices
Charlson Comorbidity Index 4.4 2.5 3.5 2.5 <.0001 34.5 3.7 2.1 3.7 2.6 0.1720 2.5
CHADS2 Score 3.3 1.2 3.0 1.1 <.0001 26.8 3.1 1.1 3.1 1.1 0.5115 1.2
Comorbid Conditions
Hypertension 12,772 80.7% 4,756 74.3% <.0001 15.4 4,397 75.9% 4,384 75.7% 0.7779 0.5
Hyperlipidemia 10,716 67.7% 2,993 46.7% <.0001 43.4 2,896 50.0% 2,937 50.7% 0.4461 1.4
Anemia 7,298 46.1% 2,862 44.7% 0.0554 2.8 2,614 45.1% 2,607 45.0% 0.8960 0.2
Diabetes 7,320 46.3% 2,292 35.8% <.0001 21.4 2,201 38.0% 2,179 37.6% 0.6734 0.8
Chronic Renal Insufficiency 5,078 32.1% 1,738 27.1% <.0001 10.8 1,670 28.8% 1,632 28.2% 0.4342 1.5
Arrhythmia 4,804 30.4% 1,487 23.2% <.0001 16.2 1,435 24.8% 1,424 24.6% 0.8126 0.4
Pneumonia 3,994 25.2% 1,864 29.1% <.0001 8.7 1,707 29.5% 1,651 28.5% 0.2515 2.1
Trauma 4,064 25.7% 1,734 27.1% 0.0309 3.2 1,596 27.6% 1,563 27.0% 0.4912 1.3
Malignant Neoplasm 3,533 22.3% 1,404 21.9% 0.5207 1.0 1,313 22.7% 1,273 22.0% 0.3721 1.7
Peripheral Arterial Disease 3,663 23.1% 834 13.0% <.0001 26.5 783 13.5% 814 14.1% 0.4035 1.6
Chronic Obstructive
Pulmonary Disease
2,576 16.3% 1,056 16.5% 0.6929 0.6 968 16.7% 962 16.6% 0.8811 0.3
Dementia 1,725 10.9% 884 13.8% <.0001 8.8 770 13.3% 768 13.3% 0.9563 0.1
Anasarca 1,666 10.5% 899 14.0% <.0001 10.7 738 12.7% 757 13.1% 0.5985 1.0
Prior Ischemic Stroke 2,685 17.0% 696 10.9% <.0001 17.7 701 12.1% 673 11.6% 0.4210 1.5
Prior Transient Ischemic Attack 625 3.9% 192 3.0% 0.0006 5.2 175 3.0% 183 3.2% 0.6676 0.8
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these HF with LVSD patients, 19,672 (67.9%) were included
in the CAD cohort and 9311 (32.1%) were included in the
non-CAD cohort (Fig. 1). After 1:1 PSM, each cohort in-
cluded 8069 patients with a median follow-up period of 22
months (Additional file 1: Table S1).
The ACM rate did not significantly differ between the
cohorts (27.1% vs 26.6%, p = 0.2153) during the first year
of the follow-up period; however, the CAD cohort had a
significantly higher ACM rate (70.6% vs 66.5%, p = 0.0069)
during the entire follow-up period. The cumulative inci-
dence rate of MI in both cohorts is consistent with that in
the primary analysis, suggesting that the risk of MI is
nearly four times higher during the first year and three
times higher at the end of the follow-up period in the
CAD cohort as compared to the non-CAD cohort. The
CAD cohort had a significantly higher cumulative inci-
dence of MI (33.3% vs 8.5%, p < 0.0001) during the first
year and during the entire follow-up period (49.5% vs
Table 1 Baseline Demographic and Clinical Characteristics of HF with LVSD Patients with and without CAD (Continued)
Baseline Characteristics of HF Patients
with LVSD
Before PSM After 1:1 PSM
CAD Cohort
(N = 15,827 )
Non-CAD Cohort
(N = 6,403)
CAD Cohort
(N = 5,792 )
Non-CAD Cohort
(N = 5,792)
N/Mean %/SD N/Mean %/SD p-value Std N/Mean %/SD N/Mean %/SD p-value Std
Prior Venous Thromboembolism 912 5.8% 535 8.4% <.0001 10.1 436 7.5% 429 7.4% 0.8046 0.5
Prior Major Bleeding* 597 3.8% 272 4.2% 0.0973 2.4 225 3.9% 239 4.1% 0.5071 1.2
Commander Criteria
Documented previous CAD 15,787 99.75% 0 0.00% N/A 5,775 99.71% 0 0.00% N/A
History of prior Coronary Artery
Bypass Graft (CABG)
933 5.89% 0 0.00% 273 4.71% 0 0.00%
History of percutaneous coronary
intervention (PCI) with or without stent
2,430 15.35% 0 0.00% 730 12.60% 0 0.00%
CAD: coronary artery disease; CHADS2: congestive HF, age ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack or venous thromboembolism; HF:
heart failure; PSM: propensity score matching; SD: standard deviation; STD: standardized difference
*Major bleeding was identified using the ICD-9-CM codes for intracranial Hemorrhage (ICD-9-CM: 430, 431, 432.0, 432.1, 432.9, 852.0x, 852.2x, 852.4x, 853.0), and
extracranial hemorrhage (ICD-9-CM: 423.0, 455.2, 455.5, 455.8, 456.0, 456.20, 459.0, 530.7, 530.82, 531.0-531.6, 532.0-532.6, 533.0-533.6, 534.0-534.6, 535.01-535.61,
537.83, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578.0, 578.1, 578.9, 593.81,599.7, 719.11, 784.7, 784.8, and 786.3)
Fig. 2 Follow-up ACM Rates among CAD vs Non-CAD Patients - after PSM. ACM: all-cause mortality; CAD: coronary artery disease; CI: confidence
interval; PSM: propensity score matching
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Fig. 3 Follow-up Cumulative Incidence of MI among CAD vs Non-CAD Patients – after PSM. CAD: coronary artery disease; CI: confidence interval;
MI: myocardial infarction; PSM: propensity score matching
Fig. 4 Follow-up Cumulative Incidence of IS among CAD vs Non-CAD Patients – after PSM CAD: coronary artery disease; CI: confidence interval;
IS: ischemic stroke; PSM: propensity score matching
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18.7%, p < 0.0001). The cumulative incidence of IS did not
significantly differ between the cohorts during the first
year of follow-up (12.0% vs 11.0%, p = 0.0633); however,
patients in the CAD cohort had a significantly higher cu-
mulative incidence of IS (25.9% vs 23.2%, p = 0.0005) dur-
ing the complete follow-up period (data not shown).
Discussion
To the best of our knowledge, this is the first real-world
study to evaluate CV-related outcomes among HF with
LVSD patients with concomitant CAD and without AF.
Despite evidence in the literature regarding CV
condition-related outcomes among HF and CAD popu-
lations separately, limited real-world evidence is available
among patients diagnosed with concomitant HF and
CAD, with LVSD and without AF in United States [9].
In this large cohort of hospitalized newly-diagnosed HF
with LVSD patients without AF, patients with CAD were
observed to have a significantly higher incidence of IS
and MI and did not significantly differ in ACM rates
compared to those without CAD. CAD is considered as
a major cause of HF with LVSD and is prevalent in
about two-thirds of the patients with HF with LVSD
[14]. Additionally, CAD has been shown to adversely
affect the prognosis in HF patients; the results of the
current study help us to understand the impact of docu-
mented CAD among HF with LVSD patients. The re-
sults also provide evidence on stroke risk among HF
with LVSD patients without AF, thereby allowing health
care providers to enhance treatment planning among
these hospitalized newly-diagnosed HF with LVSD pa-
tients without AF and with CAD.
The results of our study showed that the ACM rates
did not significantly differ between the hospitalized HF
with LVSD patients with and without CAD, probably
due to the older age of the patients in both cohorts. Eld-
erly patients have higher prevalence of multiple comor-
bidities, all of which complicate patient management
thereby increasing the mortality rates [15, 16]. Among
Medicare beneficiaries, two-thirds have multiple chronic
conditions, with prevalence ranging from 62% in those
aged 65–74 years, 75.7% in those aged 75–84 years, and
81.5% in those aged ≥85 years. However, the results of
our sensitivity analysis in the total HF with LVSD pa-
tients showed that CAD cohort had significantly higher
ACM rates than those without CAD in the entire
follow-up period. Previous studies observed CAD as a
significant predictor of mortality among HF patients
with a hazard ratio ranging from 1 to 3.4 [17, 18]. Add-
itionally, the results of our study showed that the 1-year
mortality in this elderly HF population was ~ 35% in
both cohorts, which is consistent with a previous study
conducted by Hernandez et al., which observed a 32%
mortality rate in older HF patients without AF [19].
These results highlight the poor prognosis and low sur-
vival rates among HF patients. Notably, the 1-year mor-
tality rate in HF patients is high and comparable to that
of cancer patients (~ 42%) [20]. Additionally, the given
that about 20% of the patients had evidence of malignant
neoplasm in the baseline period, the ACM rate in our
study should be interpreted with caution as the cause of
death cannot be attributed to either coronary events or
heart failure.
The results of our study showed that among patients
diagnosed with CAD, the cumulative incidence of MI
was approximately four times higher for the 1-year
post-discharge period and three times higher during the
entire follow-up period as compared to HF with LVSD
patients without CAD. The results indicate that the im-
pact of CAD on follow-up MI was larger in the first year
after HF diagnosis and declined a bit in later years but
remained significantly higher over time. In a study con-
ducted by Rusinaru et al., which evaluated 10-year out-
comes among HF patients with CAD, the risk of MI was
approximately 2.4 times higher in HF patients with CAD
as compared to those without CAD [17]. Despite the dif-
ferences in the study design and sample selection cri-
teria, these studies support the findings in the current
study, concluding that CAD is associated with higher
risk of MI among HF patients. These results highlight
the importance of developing an appropriate treatment
strategy that may reduce the risk of MI in HF patients.
Rivaroxaban 2.5 mg and 5mg (twice-daily) has been
shown to reduce the risk of composite efficacy endpoint
(ACM, MI, stroke) among HF patients in the ATLAS-2
trial [21]. Additionally, the results of an unpublished
subgroup analysis of ATLAS-2, which included clinically
diagnosed HF patients at the time of their acute coron-
ary syndrome event, showed that rivaroxaban 2.5 mg
(twice-daily) reduced the risk of MI or stroke to 11.6%
as compared to 18.6% in placebo [21]. Although these
results suggest that treatment with rivaroxaban could be
beneficial in improving overall health and thereby reduce
the health care burden in HF patients, the results of a
recent large landmark trial found that rivaroxaban 2.5
mg (twice daily) did not show a significant improvement
for cardiovascular outcomes including death, MI, or IS
among patients hospitalized with HF and reduced ejec-
tion fraction and with CAD and no AF [22]. The authors
mentioned that the most likely reason for this could be
that the thrombin-mediated events were not the signifi-
cant drivers of HF-related events in recently hospitalized
HF patients [22].
The results of our study showed that the incidence
rate of IS was significantly higher in hospitalized HF
with LVSD patients with CAD as compared to those
without CAD. Evidence from the literature suggests that
the incidence rate of stroke among HF patients with and
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without AF is approximately 0.85 and 0.69 per 100 per-
son years, respectively [23]. Additionally, in a study con-
ducted by Melgaard et al., the crude relative risk of IS
was about 2 times higher in HF patients without AF as
compared to those with AF [24]. These results highlight
the considerably high risk of stroke in HF patients with-
out AF, and the potential importance of anticoagulation
in these HF patients with sinus rhythm. In a comprehen-
sive review on the effectiveness of warfarin in reducing
the risk of stroke in HF patients without AF, it was ob-
served that warfarin had no convincing evidence of re-
ducing mortality or vascular events [25]. Although
warfarin use has shown some beneficial effect to reduce
IS, the medication was associated with serious adverse
events including increased risk of bleeding [25]. The effi-
cacy of novel oral anticoagulants (rivaroxaban) on ACM,
MI, and stroke among hospitalized HF patients without
AF and with CAD is currently being investigated in the
ongoing COMMANDER-HF trial [21]. Additionally, esti-
mating the risk of stroke and mortality in HF patients
provides an important tool to identify subset(s) of pa-
tients that may benefit from thromboprophylaxis [10].
In a sensitivity analysis of inpatient and outpatient HF
with LVSD claims, the results remained consistent and
support the robust finding of higher risk of MI in pa-
tients in the CAD cohort as compared to those in the
non-CAD cohort during the 1-year and long-term
follow-up periods. Despite the similar ACM rates be-
tween the two cohorts in the main analysis, the results
of the sensitivity analysis showed that CAD is associated
with a higher risk of ACM in HF with LVSD patients,
which is consistent with the previous studies. Addition-
ally, in contrast to the main analysis, the results of the
sensitivity analysis showed that the incidence of IS was
not significantly different in both the CAD and
non-CAD cohorts during the 1-year follow-up period,
although it is numerically higher in the CAD cohort.
Therefore, CAD qualifies as a viable candidate for
sub-classification among HF with LVSD patients due to
the condition’s high prevalence and associated burden,
irrespective of the patient being hospitalized. Further re-
search will help to identify high-risk HF patients and
provide efficient treatment, thus reducing the clinical
and economic burden of the disease.
The findings from our study should be viewed in the
context of some study limitations. Our study relied on
retrospective claims data. While claims data are ex-
tremely valuable for the efficient and effective examin-
ation of health care outcomes, treatment patterns, and
costs, they are collected for business purposes and not
with research intentions. Additionally, incorrect coding
may have resulted in misclassification. For example, the
presence of a diagnosis code on medical claims may not
indicate a positive presence of a disease and may be
incorrectly coded or included as rule-out criteria rather
than indicating the actual disease. Also, certain clinical
and disease-specific parameters are not readily available
in claims data including smoking status and HF severity,
which may have influenced study outcomes. Furthermore,
the study relied on diagnosis codes to define LVSD, result-
ing in a relatively smaller HF with LVSD population due to
inadequate coding in the claims data. Conversely, using
diagnosis codes to identify the HF with LVSD population
may have resulted in higher sensitivity, while specificity is
not certain as many people who had LVSD were not coded
as such. Similarly, as AF in the baseline period was identi-
fied using diagnosis codes, it is possible that patients with
AF were still included in the study. Further, it could be pos-
sible that AF occurred later during the post-index period,
which was not captured in our study. The requirement of
no HF diagnosis in the 12-month baseline period in our
study may have failed to identify “true newly-diagnosed HF
patients” as it is not necessary that all HF patients have an-
nual health care visits; thus, many chronic HF patients may
have been included in the study. HF is a heterogeneous
condition, and this analysis does not distinguish between
HF etiologies. Considering the fact that MI is a potent risk
factor for HF, the results of our study could be biased and
should be interpreted with caution as it is difficult to deter-
mine whether MI has caused HF or if HF caused MI. Fur-
ther analysis is needed to better understand differences in
the burden of disease in these patient groups. The current
study represented only US data from a specific subpopula-
tion (Medicare enrollees) who were mostly elderly patients.
Therefore, the general applicability of our findings to youn-
ger patients requires further study.
Conclusions
HF with LVSD patients with CAD and without AF were
at a substantially higher burden of MI and IS within the
first year of diagnosis, resulting in a poor prognosis. The
impact of CAD on CV-related outcomes is substantial,
with a higher burden of MI and IS during the entire
follow-up period. Although HF with LVSD patients with
CAD had a similar ACM rate as those without, mortality
was high, warranting optional treatment to improve pa-
tient outcomes. Secondary prevention and appropriate
management of CAD for this high-risk population may
further reduce HF-associated burden.
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